{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:11:27Z","timestamp":1788217887098,"version":"build-2803163510"},"reference-count":25,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Therapeutic options for infections caused by vancomycin-resistant enterococci are currently suboptimal. Combination regimens where fosfomycin is used alongside existing treatments are emerging given the proven synergistic potential and PK\/PD properties. In the studies presented here, we tested five vanA and five vanB clinical isolates of Enterococcus faecium using a combination of oritavancin + fosfomycin both in vitro (checkerboard, time killing) and in vivo (Galleria mellonella). The combination of oritavancin and fosfomycin increased drug susceptibility, showing a synergistic effect in 80% of isolates and an additive effect in the remaining isolates. The combination restored fosfomycin susceptibility in 85% of fosfomycin-resistant isolates. Time killing on four selected isolates demonstrated that the combination of oritavancin and fosfomycin provided a CFU\/mL reduction &gt; 2 log10 compared with the most effective drug alone and prevented the bacterial regrowth seen after 8\u201324 h at sub-inhibitory drug concentrations. In addition, the combination was also tested in a biofilm assay with two isolates, and a strong synergistic effect was observed in one isolate and an additive effect in the other. Finally, we demonstrated in vivo (Galleria mellonella) a higher survival rate of the larvae treated with the combination therapy compared to monotherapy (fosfomycin or oritavancin alone). Our study provides preclinical evidence to support trials combining oritavancin and fosfomycin for VRE BSI in humans, even when biofilm is involved.<\/jats:p>","DOI":"10.3390\/antibiotics11101334","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T21:03:10Z","timestamp":1664485390000},"page":"1334","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5739-6761","authenticated-orcid":false,"given":"Cristina","family":"Lagatolla","sequence":"first","affiliation":[{"name":"Department of Life Sciences, Trieste University, 34127 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9563-6348","authenticated-orcid":false,"given":"Jai W.","family":"Mehat","sequence":"additional","affiliation":[{"name":"School of Biosciences and Medicine, University of Surrey, Guildford GU2 7XH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Marcello","family":"La Ragione","sequence":"additional","affiliation":[{"name":"School of Biosciences and Medicine, University of Surrey, Guildford GU2 7XH, UK"},{"name":"School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5546-0715","authenticated-orcid":false,"given":"Roberto","family":"Luzzati","sequence":"additional","affiliation":[{"name":"Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6121-7009","authenticated-orcid":false,"given":"Stefano","family":"Di Bella","sequence":"additional","affiliation":[{"name":"Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34127 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Krawczyk, B., Wityk, P., Ga\u0142\u0119cka, M., and Michalik, M. (2021). The Many Faces of Enterococcus spp.-Commensal, Probiotic and Opportunistic Pathogen. Microorganisms, 9.","DOI":"10.3390\/microorganisms9091900"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1517\/14656566.8.14.2381","article-title":"Linezolid: Effectiveness and safety for approved and off-label indications","volume":"8","author":"Vardakas","year":"2007","journal-title":"Expert Opin. Pharm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.cmi.2020.04.027","article-title":"Daptomycin in the Treatment of Enterococcal Bloodstream Infections and Endocarditis: A EUCAST Position Paper","volume":"26","author":"Turnidge","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e00058-18","DOI":"10.1128\/CMR.00058-18","article-title":"The Enterococcus: A Model of Adaptability to Its Environment","volume":"32","author":"Rice","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41579-022-00682-4","article-title":"Tolerance and resistance of microbial biofilms","volume":"20","author":"Ciofu","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Vestby, L.K., Gr\u00f8nseth, T., Simm, R., and Nesse, L.L. (2020). Bacterial Biofilm and its Role in the Pathogenesis of Disease. Antibiotics, 9.","DOI":"10.3390\/antibiotics9020059"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.diagmicrobio.2018.01.029","article-title":"Oritavancin in Vitro Activity against Gram-Positive Organisms from European and United States Medical Centers: Results from the SENTRY Antimicrobial Surveillance Program for 2010\u20132014","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s10096-021-04181-x","article-title":"Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: A systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies","volume":"40","author":"Antonello","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Antonello, R.M., Principe, L., Maraolo, A.E., Viaggi, V., Pol, R., Fabbiani, M., Montagnani, F., Lovecchio, A., Luzzati, R., and Di Bella, S. (2020). Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies. Antibiotics, 9.","DOI":"10.3390\/antibiotics9080500"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"114856","DOI":"10.1016\/j.diagmicrobio.2019.06.008","article-title":"Fosfomycin for Treatment of Multidrug-Resistant Pathogens Causing Urinary Tract Infection: A Real-World Perspective and Review of the Literature","volume":"95","author":"Babiker","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1099\/jmm.0.000945","article-title":"In Vitro Activities of Daptomycin Combined with Fosfomycin or Rifampin on Planktonic and Adherent Linezolid-Resistant Isolates of Enterococcus Faecalis","volume":"68","author":"Zheng","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"115241","DOI":"10.1016\/j.diagmicrobio.2020.115241","article-title":"Synergistic Activity of Fosfomycin and Chloramphenicol against Vancomycin-Resistant Enterococcus Faecium (VREfm) Isolates from Bloodstream Infections","volume":"99","author":"Lagatolla","year":"2021","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_13","unstructured":"(2022, August 27). M100. Available online: https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/."},{"key":"ref_14","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2022, September 22). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 12.0. EUCAST, Basel. Available online: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_12.0_Breakpoint_Tables.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1128\/JCM.01121-14","article-title":"When Does 2 plus 2 Equal 5? A Review of Antimicrobial Synergy Testing","volume":"52","author":"Doern","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1128\/JCM.42.5.1915-1922.2004","article-title":"Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas Aeruginosa from Patients with Cystic Fibrosis","volume":"42","author":"Moskowitz","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106362","DOI":"10.1016\/j.ijantimicag.2021.106362","article-title":"Zidovudine in Synergistic Combination with Fosfomycin: An in Vitro and in Vivo Evaluation against Multidrug-Resistant Enterobacterales","volume":"58","author":"Antonello","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/00185787211032364","article-title":"Combination Therapy of Chloramphenicol and Daptomycin for the Treatment of Infective Endocarditis Secondary to Multidrug Resistant Enterococcus faecium","volume":"57","author":"Shah","year":"2022","journal-title":"Hosp. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14656566.2018.1479397","article-title":"Combatting resistant enterococcal infections: A pharmacotherapy review","volume":"19","author":"Mercuro","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"106215","DOI":"10.1016\/j.ijantimicag.2020.106215","article-title":"In vitro activity of eravacycline and mechanisms of resistance in enterococci","volume":"56","author":"Boukthir","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1089\/mdr.2020.0171","article-title":"Therapeutic Options for Infections due to vanB Genotype Vancomycin-Resistant Enterococci","volume":"27","author":"Riccardi","year":"2021","journal-title":"Microb. Drug. Resist."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/IDR.S54125","article-title":"Vancomycin-resistant enterococcal infections: Epidemiology, clinical manifestations, and optimal management","volume":"8","author":"Crank","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1128\/AAC.02420-12","article-title":"High Activity of Fosfomycin and Rifampin against Methicillin-Resistant Staphylococcus Aureus Biofilm in Vitro and in an Experimental Foreign-Body Infection Model","volume":"58","author":"Mihailescu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1128\/AAC.03006-15","article-title":"Oritavancin Combinations with \u03b2-Lactams against Multidrug-Resistant Staphylococcus Aureus and Vancomycin-Resistant Enterococci","volume":"60","author":"Smith","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijantimicag.2019.04.010","article-title":"Efficacy of Oritavancin Alone and in Combination against Vancomycin-Susceptible and -Resistant Enterococci in an in-Vivo Galleria Mellonella Survival Model","volume":"54","author":"Meyer","year":"2019","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/10\/1334\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:42:13Z","timestamp":1760143333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/10\/1334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["antibiotics11101334"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11101334","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}